On Friday, Akebia Therapeutics Inc (NASDAQ: AKBA) was -2.61% drop from the session before settling in for the closing price of $2.30. A 52-week range for AKBA has been $0.80 – $2.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -8.86% over the last five years. When this article was written, the company’s average yearly earnings per share was at -9.12%. With a float of $207.59 million, this company’s outstanding shares have now reached $211.54 million.
The firm has a total of 167 workers. Let’s measure their productivity. In terms of profitability, gross margin is 63.13%, operating margin of -20.45%, and the pretax margin is -27.07%.
Akebia Therapeutics Inc (AKBA) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Akebia Therapeutics Inc stocks. The insider ownership of Akebia Therapeutics Inc is 4.85%, while institutional ownership is 24.90%. The most recent insider transaction that took place on May 13 ’24, was worth 15,140. In this transaction SVP, Chief Legal Officer of this company sold 12,016 shares at a rate of $1.26, taking the stock ownership to the 651,243 shares. Before that another transaction happened on May 13 ’24, when Company’s SVP, Chief Operating Officer sold 34,840 for $1.26, making the entire transaction worth $43,898. This insider now owns 672,092 shares in total.
Akebia Therapeutics Inc (AKBA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.12% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
You can see what Akebia Therapeutics Inc (AKBA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.22, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.16 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Analysing the last 5-days average volume posted by the [Akebia Therapeutics Inc, AKBA], we can find that recorded value of 1.74 million was lower than the volume posted last year of 2.48 million. As of the previous 9 days, the stock’s Stochastic %D was 68.66%. Additionally, its Average True Range was 0.11.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 85.47%, which indicates a significant increase from 75.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.60% in the past 14 days, which was higher than the 57.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.99, while its 200-day Moving Average is $1.50. Now, the first resistance to watch is $2.32. This is followed by the second major resistance level at $2.40. The third major resistance level sits at $2.45. If the price goes on to break the first support level at $2.19, it is likely to go to the next support level at $2.14. Now, if the price goes above the second support level, the third support stands at $2.06.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
There are 218,181K outstanding shares of the company, which has a market capitalization of 488.73 million. As of now, sales total 194,620 K while income totals -51,930 K. Its latest quarter income was 37,430 K while its last quarter net income were -20,040 K.
